Be a Smart Investor
Tuesday, May 23, 2017
Amgen Inc. (AMGN) Tumbled To Nearly A 4-Month Low On Drug Safety Concerns
Amgen Inc. (AMGN) and UCB announced Sunday that the EVENITY (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint.
from RTT - Before the Bell http://ift.tt/2rOBq7K
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
View mobile version
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment